Trending Topics in Gastroenterology | GastroAGI

Impact of Adenoma Detection Rate on Prevalent Colorectal Cancer Identification in a National Colonoscopy Registry

The study investigated the impact of adenoma detection rate (ADR), a key quality metric for colonoscopy, on the identification of prevalent colorectal cancer (CRC) during colonoscopy. While ADR is known to inversely correlate with post-colonoscopy CRC, its association with detecting existing CRC at the time of the procedure was less clear. Using data from a large national colonoscopy registry, the researchers analyzed both screening colonoscopies and those conducted after abnormal fecal test results. The primary aim was to assess the relationship between individual endoscopists' ADR and the likelihood of identifying CRC present during the procedure. Secondary analyses examined related quality indicators, such as detection of sessile serrated lesions and advanced precancerous lesions, while considering patient demographics, procedural factors, and endoscopist-specific variables. The findings revealed a strong positive association between higher ADR and increased detection of prevalent CRC in both screening and follow-up colonoscopies. Endoscopists with lower ADRs consistently missed more cancers, regardless of their ability to detect sessile serrated lesions. Detection of advanced precancerous lesions also mirrored ADR patterns, suggesting overlapping skills in identifying adenomas and invasive cancers. The study concluded that many post-colonoscopy CRCs might arise from cancers missed during the initial examination, not just from undetected precursor lesions progressing over time. These results underscore the importance of maintaining high ADRs and enhancing colonoscopy quality improvement initiatives. Improving ADR can lead to better recognition of early-stage cancers and subtle neoplastic lesions, ultimately reducing the burden of CRC.

Enfortumab vedotin for gastric and esophageal cancers

Enfortumab vedotin (EV), a Nectin-4–directed antibody–drug conjugate, has been evaluated for its antitumor activity and safety in patients with heavily pretreated gastric and esophageal cancers through the EV-202 study, a phase II, open-label, multicenter trial. Below is a detailed summary of the findings regarding its use in this context: ### Study Design & Patient Population - **Objective:** The study aimed to assess the efficacy and safety of EV in patients with advanced or metastatic gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC) who had previously undergone platinum-based chemotherapy and immune checkpoint inhibitors. - **Dosing Regimen:** Patients received EV intravenously at a dose of 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity. ### Primary and Secondary Endpoints - **Primary Endpoint:** The objective response rate (ORR) was evaluated per RECIST v1.1. - **Secondary Endpoints:** These included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. ### Key Findings #### 1. **Efficacy Results** - **Gastroesophageal Adenocarcinoma (GEA) Cohort:** - ORR: 9.5% (4 out of 42 patients responded to treatment). - DCR: 47.6%. - Median DOR: 10.3 months. - Median PFS: 3.1 months. - Median OS: 8.3 months. - Predefined efficacy threshold (≥17.5% ORR) was **not met** in this cohort. - **Esophageal Squamous Cell Carcinoma (ESCC) Cohort:** - ORR: 18.2% (8 out of 44 patients responded to treatment). - DCR: 45.5%. - Median DOR: 3.9 months. - Median PFS: 2.1 months. - Median OS: 7.4 months. - Predefined efficacy threshold (≥17.5% ORR) was **met** in this cohort, indicating promising antitumor activity. #### 2. **Nectin-4 Expression** - High expression of Nectin-4, the target of EV, was observed in the majority of patients (93.9% in GEA and 97.6% in ESCC). - However, no clear correlation was identified between Nectin-4 expression levels and treatment response. #### 3. **Safety Profile** - Treatment-related adverse events (AEs) were common, occurring in 85.7% of GEA patients and 95.5% of ESCC patients. - Most AEs were manageable, with commonly reported mild AEs including pruritus, alopecia, dysgeusia, rash maculopapular, fatigue, and diarrhea. - Severe AEs (Grade ≥3) were reported in approximately 28% of patients in both cohorts, including rash, hyperglycemia, and neutropenia. - No treatment-related deaths were observed. - Dose interruptions (~33%) and reductions (~25%) were required in some patients to manage toxicity. #### 4. **Response Timing** - Median time to partial response was 1.7–1.8 months, suggesting early measurable effects in responders. #### 5. **Comparison with Other Treatments** - The ORR observed with EV (9.5% in GEA, 18.2% in ESCC) was modestly higher than that reported with anlotinib monotherapy (8.4%), demonstrating EV's activity even in heavily pretreated populations. #### 6. **Quality of Life** - Quality-of-life assessments (EQ-5D-5L and pain evaluations) indicated stable or slightly improved quality of life during EV treatment. ### Clinical Implications - **For ESCC:** EV demonstrated moderate efficacy and manageable safety, meeting the threshold for antitumor activity. This suggests that EV could serve as a potential salvage therapy for ESCC patients who have failed prior chemotherapy and immunotherapy. These results support further investigation of EV, particularly in combination regimens. - **For GEA:** The efficacy of EV in GEA was limited, as the predefined threshold for efficacy was not met. This indicates that EV may have less clinical relevance in this subgroup. ### Conclusion Enfortumab vedotin showed manageable safety and moderate efficacy in patients with heavily pretreated gastric and esophageal cancers. While its clinical relevance was limited in gastroesophageal adenocarcinoma, it demonstrated promising activity in esophageal squamous cell carcinoma, warranting further exploration, particularly in combination with other therapies.

VEGF bispecific fast lane

The term "VEGF bispecific fast lane" refers to the accelerated development and competitive landscape surrounding VEGF bispecific antibodies in oncology, particularly in the context of Pfizer's strategic initiatives and the broader industry trends. Here's a detailed breakdown of the concept: ### 1. **What is VEGF Bispecific Therapy?** VEGF bispecific antibodies are a class of immunotherapies that target two pathways simultaneously: - **PD-(L)1 blockade**: Enhancing immune activation by inhibiting the PD-(L)1 pathway, which tumors exploit to evade immune system attacks. - **VEGF inhibition**: Normalizing tumor vasculature and disrupting the blood supply tumors need to grow, leveraging anti-angiogenesis mechanisms. This dual-action approach has shown promise in preclinical and early clinical trials, offering a synergistic effect that could surpass the efficacy of single-pathway inhibitors like Keytruda (pembrolizumab). ### 2. **Why is it a "Fast Lane"?** The term "fast lane" reflects the urgency and rapid progress in developing VEGF bispecific therapies due to their potential to revolutionize cancer treatment. Key factors contributing to the fast lane include: #### a. **Intense Competition Among Global Players** - Pfizer's PF-08634404 is entering pivotal phase 3 trials for **non-small cell lung cancer (NSCLC)** and **colorectal cancer (CRC)**, directly competing with other VEGF bispecific candidates like: - **Ivonescimab** (Summit/Akeso): Already in phase 3 trials for NSCLC and CRC. - **Pumitamig** (BioNTech/Bristol Myers Squibb): Set to begin phase 3 trials in 2026. - The competition is fierce, with companies racing to achieve regulatory approval and market dominance in this emerging class. #### b. **High Confidence in the Molecule** - Pfizer is launching fully-fledged phase 3 trials for PF-08634404 from the outset, skipping adaptive phase 2/3 designs used by competitors. This signals strong confidence in the molecule's efficacy and safety profile, based on preliminary phase 2 data. #### c. **Strategic Timing** - Pfizer's first trial readouts are expected in late 2026 to early 2027, aligning with competitor milestones (e.g., Akeso's Harmoni-3 results in H2 2026 and H1 2027). This timing positions Pfizer to compete directly in the fast-evolving market. #### d. **Innovative Mechanistic Rationale** - The combination of PD-(L)1 and VEGF blockade represents the next major evolution in immuno-oncology, following checkpoint inhibitors. This innovative approach is driving rapid investment and trial launches. ### 3. **Pfizer’s Position in the Fast Lane** Pfizer has made significant moves to secure its position in the VEGF bispecific fast lane: - **$1.25 Billion Investment**: Pfizer licensed PF-08634404 (originally SSGJ-707) from China's 3SBio in May 2025, underscoring its commitment to oncology innovation as COVID-19 revenues decline. - **Global Phase 3 Trials**: - NSCLC: PF-08634404 + chemotherapy vs. Keytruda + chemotherapy, split by histology (squamous vs. non-squamous). - CRC: PF-08634404 vs. Avastin + chemotherapy in microsatellite-stable (MSS), non–BRAF-mutant patients—a challenging subgroup with low immunotherapy response rates. - **Mechanistic Validation**: Preclinical studies and early clinical data have shown strong anti-tumor activity and synergy between PD-(L)1 and VEGF blockade, although toxicity concerns remain. ### 4. **Challenges and Opportunities** #### Challenges: - **Toxicity Concerns**: Early phase 2 data from 3SBio highlighted potential safety issues, which will need to be addressed in phase 3 trials. - **Competitive Pressure**: Pfizer faces direct competition from Akeso, BioNTech/Bristol Myers Squibb, and other Asian biotech pioneers who have led the innovation in bispecific immuno-oncology. #### Opportunities: - **Market Impact**: Success in phase 3 trials could establish Pfizer as a top-tier player in bispecific immunotherapy, rivaling Merck's Keytruda dominance in lung and colorectal cancer markets. - **Innovation Leadership**: By advancing PF-08634404, Pfizer aims to close the innovation gap and position itself as a leader in the next generation of cancer treatments. ### 5. **Industry Context** VEGF bispecifics are considered the next frontier in oncology, combining immune activation and anti-angiogenesis to tackle difficult-to-treat cancers like MSS colorectal cancer and squamous NSCLC. The "fast lane" refers not only to the speed of development but also to the high stakes and intense competition among pharmaceutical giants and biotech innovators. ### 6. **Future Outlook** The success of VEGF bispecific therapies, including PF-08634404, will depend on: - Phase 3 trial outcomes (expected late 2026 to early 2027 for Pfizer). - Regulatory approval timelines. - Commercial adoption and market penetration. - Long-term safety and efficacy data. In summary, the VEGF bispecific fast lane represents a high-stakes race in oncology innovation, with Pfizer, Akeso, BioNTech/Bristol Myers Squibb, and others vying to lead the next wave of cancer treatment advancements.

Radiofrequency ablation for malignant biliary obstruction

Radiofrequency ablation (RFA) is a minimally invasive procedure that uses heat generated by high-frequency electrical currents to destroy abnormal or malignant tissue. In the context of malignant biliary obstruction (MBO), which occurs when cancer blocks the bile ducts and prevents bile from flowing properly, RFA has been studied as a potential adjunct therapy to biliary stenting. Biliary stenting is the standard treatment for MBO, as it helps restore bile flow and alleviate symptoms like jaundice and digestive issues. However, stents can become clogged over time due to tumor growth or bile sludge. Researchers have explored whether adding RFA to stenting could improve outcomes for patients with MBO. ### Role of RFA in Malignant Biliary Obstruction: 1. **Tumor Control**: RFA may help destroy malignant tissue within or near the bile ducts. This can potentially slow tumor progression, providing a local or systemic benefit that could improve survival outcomes. 2. **Survival Benefit**: Studies have shown that adding RFA to biliary stenting may improve short-term survival, particularly in patients with cholangiocarcinoma (a type of bile duct cancer). This suggests that RFA might offer some therapeutic advantage beyond simply relieving bile duct obstruction. 3. **Stent Patency**: Despite its tumor-destroying capabilities, RFA does not seem to prolong the functional lifespan of biliary stents. Stents still tend to clog or fail at similar rates whether RFA is used or not. 4. **Safety Considerations**: While RFA may offer survival benefits, it also comes with risks. One notable concern is an increased incidence of cholecystitis (inflammation of the gallbladder) in patients who undergo RFA. This highlights the importance of careful patient selection and close monitoring during and after the procedure. ### Summary: RFA is not a solution for improving stent functionality, but it may enhance survival in patients with malignant biliary obstruction, particularly those with cholangiocarcinoma. Its role appears to focus more on controlling tumor growth rather than directly addressing stent patency. However, its use requires caution due to potential complications like cholecystitis, emphasizing the need for individualized treatment planning.

Big Bang Moment

The "Big Bang" moment, as described in the context of bowel cancer research, refers to a defining early event in the development of the cancer that determines how the tumor will grow and interact with the immune system throughout its life. This moment is pivotal because it sets the stage for the tumor's characteristics and its ability to evade immune detection. Here’s a detailed breakdown of what happens during this "Big Bang" moment: 1. **Immune Escape**: At this early stage, cancer cells develop mechanisms to hide from the immune system. They disrupt genes that are essential for immune detection, preventing the immune system from recognizing and attacking the tumor. This immune evasion allows the cancer to grow unchecked. 2. **Reduction in Neoantigens**: Neoantigens are specific proteins on the surface of cancer cells that act as "red flags" for the immune system. During the "Big Bang," bowel cancer cells reduce the number of neoantigens displayed on their surface. With fewer neoantigens, the immune system struggles to identify the tumor as a threat. 3. **Epigenetic Changes**: The study revealed that epigenetic modifications—chemical changes that alter how DNA is read—play a significant role in this process. These changes contribute to the reduction of neoantigens and the immune escape mechanism. 4. **Long-Term Impact**: Once this immune escape occurs during the "Big Bang," the tumor’s interaction with the immune system remains largely consistent as it grows. This explains why many bowel cancers are resistant to immunotherapy, which relies on the immune system to attack the tumor. ### Implications of the "Big Bang" Moment: - **Resistance to Immunotherapy**: Since the immune escape happens early and remains stable, only about 15% of bowel cancers respond well to immunotherapy treatments. Most tumors remain hidden from immune cells due to the lack of neoantigens. - **Potential Treatment Strategies**: The research suggests that combining immunotherapy with drugs that modify epigenetics could help reverse the immune escape. By increasing neoantigen production, these drugs could make tumors visible again to the immune system, potentially improving the effectiveness of immunotherapy and vaccines for a larger group of patients. - **Personalized Medicine**: Understanding this "Big Bang" moment provides insights into the early stages of tumor development, enabling researchers to design more personalized treatments that target immune evasion before the cancer progresses. In summary, the "Big Bang" moment is a critical early event in bowel cancer development where the tumor gains the ability to evade immune detection, shaping its growth and resistance to treatments throughout its life. This discovery opens new avenues for therapeutic strategies aimed at reversing immune escape and improving outcomes for patients.

FDA grant Fast Track Designation to a new drug combination for metastatic CRC

Yes, the FDA has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer (CRC). This combination includes **alnodesertib** (an ATR inhibitor) and **low-dose irinotecan**. The designation was given due to the promising results observed in patients with metastatic CRC whose tumors lack the **ATM DNA-repair protein**. The mechanism behind this drug combo is particularly innovative. Irinotecan works by damaging the DNA of cancer cells, while alnodesertib blocks the cancer cells' ability to repair that damage. Tumors that are **ATM-deficient** already have compromised DNA repair systems, making this dual approach especially effective. In clinical trials, many patients with ATM-deficient tumors experienced meaningful tumor shrinkage, offering hope to a group of patients who previously had limited treatment options. The Fast Track Designation is significant because it aims to accelerate the development, review, and availability of therapies that address unmet medical needs, particularly in high-need patient populations. This designation will help expedite the process of bringing this potentially transformative therapy to patients battling metastatic CRC.

Bemarituzumab in First-Line Gastric Cancer — FORTITUDE Trials

Bemarituzumab is a first-in-class monoclonal antibody that targets FGFR2b (fibroblast growth factor receptor 2b), a key driver in a subset of gastric cancers characterized by FGFR2b overexpression. The FORTITUDE clinical trial program explores the efficacy and safety of bemarituzumab in various settings, primarily focusing on its use in first-line treatment for gastric cancer. Below is a detailed breakdown of the FORTITUDE trials relevant to first-line gastric cancer: --- ### **1. FORTITUDE-101:** - **Objective:** Evaluated the combination of bemarituzumab with chemotherapy (mFOLFOX6) versus chemotherapy plus placebo in patients with FGFR2b-positive gastric cancer. - **Results:** - Bemarituzumab plus chemotherapy significantly **improved overall survival (OS)** compared to chemotherapy alone. - **Median OS:** - Bemarituzumab + mFOLFOX6: **17.9 months** - Placebo + mFOLFOX6: **12.5 months** - **Hazard Ratio (HR):** 0.61 (indicating a 39% reduction in the risk of death). - **Statistical Significance:** p = 0.005. - This trial demonstrates the potential benefit of bemarituzumab in improving survival for patients with FGFR2b-positive gastric cancer. --- ### **2. FORTITUDE-102:** - **Objective:** A Phase 1b/3 study designed to evaluate bemarituzumab in combination with chemotherapy and nivolumab versus chemotherapy and nivolumab alone in FGFR2b-positive first-line gastric cancer. - **Status:** This trial was **stopped**. The specific reasons for discontinuation are not provided in the context, but it is common for trials to be stopped due to various factors, including safety concerns, lack of efficacy, or strategic decisions. --- ### **3. FORTITUDE-103:** - **Objective:** A Phase 1b/2 study investigating bemarituzumab in combination with or without nivolumab across different oral chemotherapy regimens for first-line gastric cancer patients. - **Update:** The trial has successfully **completed patient enrollment**, indicating that the study is progressing as planned. Results from this study will provide further insights into the potential of bemarituzumab in combination with different therapeutic approaches. --- ### **Broader Development – FORTITUDE-30:** - While not limited to gastric cancer, the Phase 1b/2 **FORTITUDE-30 basket study** is exploring bemarituzumab as a monotherapy in patients with solid tumors that overexpress FGFR2b. This study could expand the use of bemarituzumab beyond gastric cancer to other FGFR2b-driven malignancies. --- ### **Conclusion:** The FORTITUDE clinical trial program underscores the promise of bemarituzumab as a targeted therapy for FGFR2b-positive gastric cancer, particularly in the first-line setting. The positive results from FORTITUDE-101 highlight its potential to improve overall survival when combined with chemotherapy. The ongoing FORTITUDE-103 study and the broader FORTITUDE-30 basket trial may further solidify bemarituzumab's role in treating FGFR2b-overexpressing tumors, while the discontinuation of FORTITUDE-102 highlights the challenges of combining multiple therapies. Future results from these studies will be crucial to defining bemarituzumab's place in the treatment landscape for gastric cancer and potentially other cancers.

Intratumoral heterogeneity and immunotherapy resistance

Intratumoral heterogeneity (ITH) plays a critical role in immunotherapy resistance, significantly influencing the success or failure of immune checkpoint inhibitor therapies. ITH refers to the genetic, epigenetic, and phenotypic diversity observed within individual tumors and across metastatic sites. This heterogeneity enables tumors to adapt to selective pressures exerted by the immune system and therapeutic interventions, creating challenges for achieving durable responses with immunotherapy. ### Key Factors Linking ITH to Immunotherapy Resistance 1. **Intrinsic ("Hardware") Mechanisms**: - **Genetic Diversity**: Tumors often contain subclonal populations with distinct genetic mutations. These mutations may confer resistance to immune checkpoint inhibitors by altering the expression of antigens or immune-related pathways, such as major histocompatibility complex (MHC) molecules, interferon signaling, or immune checkpoints like PD-L1. - **Epigenetic Modifications**: Epigenetic changes, such as DNA methylation or histone modifications, can regulate immune-related gene expression, leading to immune evasion. For example, silencing of tumor antigens or genes involved in immune recognition can reduce the effectiveness of immunotherapy. 2. **Extrinsic ("Software") Mechanisms**: - **Tumor Microenvironment (TME)**: The TME is composed of immune cells, stromal cells, and secreted factors that can vary significantly within different regions of the tumor. Certain areas may be immunosuppressive, with high levels of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), or immunosuppressive cytokines like TGF-β and IL-10, shielding tumor cells from immune attack. - **Immune Editing**: Tumor cells and immune cells are engaged in a dynamic coevolution process, where immune pressure selects for tumor variants that are less immunogenic or better equipped to evade immune detection. This process results in the survival of resistant clones within the tumor. ### Mechanisms of Resistance Driven by ITH - **Innate Resistance**: Some tumor cells are inherently resistant to immunotherapy due to their genetic or epigenetic makeup. For example, tumors with low mutational burden or defective antigen presentation machinery may fail to elicit a robust immune response. - **Acquired Resistance**: Tumor cells can adapt to immunotherapy over time, often through mechanisms like upregulation of immune checkpoints (e.g., PD-L1), loss of tumor antigens, or recruitment of immunosuppressive cells to the TME. ### Therapeutic Implications of ITH in Immunotherapy Given the role of ITH in driving resistance, personalized therapeutic strategies are essential to improve immunotherapy outcomes. Key approaches include: 1. **ITH Profiling**: - Comprehensive analysis of tumor heterogeneity, using techniques like single-cell sequencing, spatial transcriptomics, and multi-region sampling, can identify specific subclonal populations and resistance mechanisms. - Biomarker-driven approaches can help predict which patients are likely to respond to specific immunotherapies. 2. **Combination Immunotherapy**: - Combining immune checkpoint inhibitors with other treatments, such as targeted therapies, chemotherapy, or radiation, may help address different resistance mechanisms simultaneously. - Pairing immunotherapy with agents that modulate the TME, such as inhibitors of Tregs, MDSCs, or TGF-β, may improve immune infiltration and efficacy. 3. **Targeting Tumor Evolution**: - Therapies aimed at preventing or reversing immune editing, such as adoptive cell therapies (e.g., TILs or CAR-T cells), can target resistant tumor clones directly. - Epigenetic therapies that restore antigen expression or enhance immune recognition may counteract immune evasion. 4. **Novel Immune Targets**: - Exploring immune checkpoints beyond PD-1/PD-L1, such as LAG-3, TIM-3, TIGIT, or VISTA, may provide alternative pathways to overcome resistance. - Vaccines targeting neoantigens derived from tumor-specific mutations could enhance immune responses against heterogeneous tumors. ### Conclusion Intratumoral heterogeneity represents a formidable barrier to effective immunotherapy, as it allows tumors to adapt and evade immune surveillance. Understanding the interplay between ITH and immunotherapy resistance through advanced profiling techniques and molecular analyses is critical for developing personalized and combinatorial treatment strategies. By addressing the diverse mechanisms of resistance driven by ITH, the next generation of immunotherapies has the potential to achieve more durable and complete responses in cancer patients.

Surveillance for Esophageal Cancer from SANO Trial

Surveillance for esophageal cancer, particularly in the context of patients treated with neoadjuvant chemoradiotherapy (nCRT), is a critical area of research and clinical practice. Active surveillance is an approach where patients are closely monitored after nCRT instead of proceeding directly to surgery. This strategy has been shown to be non-inferior to immediate surgery for select patients, but it comes with challenges, especially in identifying which patients are suitable for this approach. The SANO trial analyzed 750 esophageal or junctional cancer patients treated with the CROSS regimen of nCRT. It found that only 37% achieved a complete clinical response (CCR) 12 weeks after treatment, and of those who entered active surveillance (198 patients), only 25% maintained sustained CCR over a median follow-up of 54 months. This highlights the limited success of achieving and maintaining full remission with active surveillance. Key findings from the study include: - Patients with higher clinical nodal categories (cN2–3) had lower odds of achieving CCR and a twofold higher risk of recurrence, making them less suitable for active surveillance. - Tumor histology influenced outcomes, with squamous cell carcinoma showing better distant progression-free survival compared to adenocarcinoma. - Standard clinical factors like age, sex, tumor differentiation, and tumor size were not reliable predictors of CCR or sustained CCR. - Current diagnostic tools, such as PET-CT and endoscopic ultrasound, have limited accuracy in detecting residual disease. The study underscores the need for advanced biomarkers, such as radiomics, circulating tumor DNA (ctDNA), and FAPI PET-CT, to improve the prediction of treatment response and guide decisions about active surveillance versus surgery. This approach could help optimize treatment strategies and reduce unnecessary delays for high-risk patients.

Pembrolizumab in microsatellite-stable CRC

### Explanation of Key Terms: #### **Microsatellite-Stable (MSS) Colorectal Cancer (CRC):** Microsatellite stability refers to the genetic stability of certain DNA sequences called microsatellites, which are short, repetitive sequences scattered throughout the genome. In microsatellite-stable (MSS) colorectal cancer (CRC), these sequences remain intact, indicating that the tumor lacks defects in the mismatch repair (MMR) system. MSS tumors are characterized by low levels of mutations and are typically less responsive to immunotherapy compared to microsatellite instability-high (MSI-H) tumors, which have defective MMR and high mutation rates. #### **Tumor Mutational Burden-High (TMB-H):** Tumor mutational burden (TMB) measures the number of mutations per megabase (mut/Mb) of DNA within a tumor genome. TMB-H refers to tumors with a high mutation load, often defined as ≥10 mutations per megabase. High TMB is thought to generate more neoantigens, making tumors potentially more recognizable to the immune system. In certain cancers, TMB-H predicts better responses to immune checkpoint inhibitors (ICIs) like pembrolizumab. However, in MSS CRC, high TMB alone does not reliably predict immunotherapy efficacy. #### **Metastatic Colorectal Cancer (mCRC):** Metastatic colorectal cancer (mCRC) is an advanced stage of CRC where cancer has spread from the colon or rectum to other parts of the body, such as the liver, lungs, or lymph nodes. Treatment for mCRC often includes chemotherapy, targeted therapy, and, in some cases, immunotherapy depending on the tumor's genetic profile. #### **Pembrolizumab:** Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. By blocking PD-1, pembrolizumab prevents cancer cells from evading immune detection, allowing the immune system to attack the tumor. It is FDA-approved for various cancers, including MSI-H CRC, but its effectiveness in MSS CRC is limited due to the immune-resistant nature of these tumors. --- ### **Summary of the Study:** This study focused on evaluating the real-world efficacy of pembrolizumab in patients with **microsatellite-stable (MSS), tumor mutational burden-high (TMB-H) metastatic colorectal cancer (mCRC)**. The researchers used data from Japan’s national C-CAT genomic database, which included 127 patients with TMB-H mCRC treated with pembrolizumab. Of these, 77 had MSS tumors, and 50 had MSI-H tumors. #### **Key Findings:** 1. **Poor Outcomes in MSS-TMB-H Subgroup:** - Patients with MSS-TMB-H mCRC had significantly worse outcomes compared to MSI-H-TMB-H patients. - Median overall survival (OS) for MSS-TMB-H was **4.5 months**, whereas MSI-H-TMB-H patients had a median OS of **33.6 months**. - Median time to treatment failure (TTF) was **2.0 months** for MSS-TMB-H versus **10.6 months** for MSI-H-TMB-H. 2. **Comparative Efficacy:** - Pembrolizumab demonstrated **shorter overall survival (OS)** and **time to treatment failure (TTF)** compared to standard later-line treatments like **trifluridine/tipiracil (FTD/TPI)** ± bevacizumab and regorafenib. - For MSS-TMB-H patients, pembrolizumab showed no survival advantage over regorafenib and performed worse than FTD/TPI ± bevacizumab. 3. **Limited Predictive Power of TMB:** - High TMB alone (≥10 muts/Mb) was not a reliable predictor of pembrolizumab response in MSS tumors. - MSI status was a stronger determinant of benefit, highlighting the importance of combining MSI and TMB profiling in treatment decisions. 4. **Genomic Insights:** - MSS-TMB-H tumors resembled MSS-TMB-L tumors genomically, explaining their poor response to pembrolizumab despite high TMB. - MSS-TMB-H CRCs were found to be "immune cold," with low T-cell infiltration and reduced immune activation. 5. **Rare Exceptions:** - Rare MSS-TMB-H cases with pathogenic **POLE mutations** (hypermutated subtype) showed exceptionally high TMB (>100 muts/Mb) and better outcomes with pembrolizumab. 6. **Predictive Biomarkers:** - Amplifications in **BCL2L1** and **SRC** (Chr20q11 region) correlated with longer progression-free survival (PFS) and overall survival (OS) under pembrolizumab treatment, suggesting these may serve as prognostic markers. --- ### **Clinical Implications:** 1. **Pembrolizumab Limitations:** - Pembrolizumab should **not be considered a standard later-line therapy** for MSS-TMB-H mCRC due to minimal efficacy in this subgroup. - MSI status remains the key biomarker for pembrolizumab eligibility. 2. **Alternative Therapies:** - Standard treatments like **FTD/TPI ± bevacizumab** and **regorafenib** demonstrated better survival outcomes in MSS-TMB-H mCRC and should remain the preferred options for later-line therapy. 3. **Biomarker Refinement:** - The study emphasizes the need for **refined biomarker-based therapy approvals**, recommending combined MSI and TMB profiling to guide immunotherapy decisions. 4. **Research Direction:** - Future studies should explore alternative strategies for treating MSS-TMB-H mCRC, including therapies targeting the tumor microenvironment or novel combinations of immunotherapy and other modalities. --- ### **Core Conclusion:** Pembrolizumab demonstrates **limited efficacy** in MSS-TMB-H metastatic colorectal cancer due to genomic and immunologic similarities to MSS-TMB-L disease, which is inherently resistant to immune checkpoint inhibitors. The study underscores the importance of alternative, non-immunotherapy strategies for this subgroup and highlights the need for improved biomarker-based treatment approaches.